Palisade Bio, Inc.
PALI Healthcare Biotechnology
Palisade Bio, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $250,000.00. In the quarter to June 2026, revenue grew 19,900.0%, EPS grew 91.4% and free cash flow fell 318.4%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.
Follow PALI
Palisade Bio, Inc. (PALI) EV/Sales
As of 16 October 2026, Palisade Bio, Inc. (PALI) trades at a EV/Sales of 230×. Over the past ten years it has ranged from −873× (December 2022) to 20,647,674,913× (February 2015); the current reading is higher than 58% of that period. That is above the Biotechnology industry median of 9.2× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2023 | −31.9× | — |
| FY2020 | 1,117× | — |
| FY2019 | −176× | — |
| FY2018 | 8.0× | (82.18%) |
| FY2017 | 44.9× | (96.74%) |
| FY2016 | 1,378× | (87.67%) |
| FY2015 | 11,173× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 420× | 5,019.68% |
| Mar 2023 | 8.2× | (99.27%) |
| Dec 2020 | 1,117× | — |
| Sep 2020 | −210× | — |
| 22 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| NAUT Nautilus Biotechnology, Inc. compare | n/m |
| CABA Cabaletta Bio, Inc. compare | n/m |
| IPSC Century Therapeutics, Inc. compare | 1.4× |
| ABEO Abeona Therapeutics Inc. compare | 4.6× |
| PRLD Prelude Therapeutics Incorporated compare | 7.5× |
| XFOR X4 Pharmaceuticals, Inc. compare | 12.4× |
| OCGN Ocugen, Inc. compare | 36.2× |
| EYPT EyePoint, Inc. compare | 40.8× |
| PALI Palisade Bio, Inc. | 230× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)